| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mg |
|
||
| 250mg |
|
||
| 10g |
|
||
| Other Sizes |
|
Naringin (also known as Naringoside; AI319008; Aurantiin; AI3-19008), a flavanone-7-O-glycoside, is a novel, potent, natural flavanone glycoside found in citrus fruits (e.g. tomatoes and grapefruits). It exerts a wide range of pharmacological effects such as antioxidant activity, blood lipid lowering, anticancer activity, and inhibition of cytochrome P450 enzymes. It inhibits hepatic P-glycoprotein (P-gp) and some drug-metabolizing cytochrome P450 enzymes, including CYP3A4 and CYP1A2, which may result in drug-drug interactions.
| ln Vitro |
Naringin inhibits the activation of the NF-κ B signaling pathway. In HBZY-1 cells, naringenin prevents oxidative stress injury, inflammatory response, and proliferation brought on by high glucose[1]. AGS cancer cell growth is inhibited by naringin in a time- and dose-dependent way. In Naringin-treated AGS cells, phosphorylation of PI3K and its activated downstream targets, p-Akt and p-mTOR, is markedly reduced at 2 mM. In AGS cells, naringin causes autophagic cell death. In AGS cells, naringin triggered the autophagy-related protein[2]. PC12 cells are shielded from 3-NP neurotoxicity by naringin. When 3-NP-induced PC12 cells are treated with naringin, the release of lactate dehydrogenase is reduced. By raising the amount of reduced glutathione and the activities of enzymatic antioxidants, naringin therapy improves antioxidant defense[3].
|
||
|---|---|---|---|
| ln Vivo |
Naringin treatment considerably reduces renal damage in diabetic rats and causes a large rise in body weight. In diabetic rats, naringin administration successfully reduces collagen deposition and renal interstitial fibrosis. Naringin treatment may cause ROS and MDA levels to drop while SOD and GSH-Px activities rise[1]. Naringin administered orally dramatically enhances memory and learning capacities. The insulin signaling pathway is markedly enhanced by naringin[3].
|
||
| Animal Protocol |
|
||
| References |
|
||
| Additional Infomation |
Naringin is a disaccharide derivative that is (S)-naringenin substituted by a 2-O-(alpha-L-rhamnopyranosyl)-beta-D-glucopyranosyl moiety at position 7 via a glycosidic linkage. It has a role as a metabolite, an antineoplastic agent and an anti-inflammatory agent. It is a disaccharide derivative, a dihydroxyflavanone, a member of 4'-hydroxyflavanones, a (2S)-flavan-4-one and a neohesperidoside. It is functionally related to a (S)-naringenin.
Naringin has been reported in Salvia officinalis, Citrus reticulata, and other organisms with data available. See also: Naringenin (subclass of); Drynaria fortunei root (part of). |
| Molecular Formula |
C27H32O14
|
|
|---|---|---|
| Molecular Weight |
580.53
|
|
| Exact Mass |
580.179
|
|
| CAS # |
10236-47-2
|
|
| Related CAS # |
Naringin Dihydrochalcone;18916-17-1
|
|
| PubChem CID |
442428
|
|
| Appearance |
White to light yellow solid powder
|
|
| Density |
1.2±0.1 g/cm3
|
|
| Boiling Point |
928.1±65.0 °C at 760 mmHg
|
|
| Melting Point |
166 °C
|
|
| Flash Point |
308.5±27.8 °C
|
|
| Vapour Pressure |
0.0±0.3 mmHg at 25°C
|
|
| Index of Refraction |
1.564
|
|
| LogP |
-0.18
|
|
| Hydrogen Bond Donor Count |
8
|
|
| Hydrogen Bond Acceptor Count |
14
|
|
| Rotatable Bond Count |
6
|
|
| Heavy Atom Count |
41
|
|
| Complexity |
884
|
|
| Defined Atom Stereocenter Count |
11
|
|
| SMILES |
C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)O[C@@H]2[C@H]([C@@H]([C@H](O[C@H]2OC3=CC(=C4C(=O)C[C@H](OC4=C3)C5=CC=C(C=C5)O)O)CO)O)O)O)O)O
|
|
| InChi Key |
DFPMSGMNTNDNHN-JJLSSNRUSA-N
|
|
| InChi Code |
InChI=1S/C27H32O14/c1-10-20(32)22(34)24(36)26(37-10)41-25-23(35)21(33)18(9-28)40-27(25)38-13-6-14(30)19-15(31)8-16(39-17(19)7-13)11-2-4-12(29)5-3-11/h2-7,10,16,18,20-30,32-36H,8-9H2,1H3/t10-,16?,18+,20-,21+,22+,23-,24+,25+,26-,27+/m0/s1
|
|
| Chemical Name |
7-(((2S,3R,4S,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-(((2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)tetrahydro-2H-pyran-2-yl)oxy)-5-hydroxy-2-(4-hydroxyphenyl)chroman-4-one
|
|
| Synonyms |
|
|
| HS Tariff Code |
2934.99.9001
|
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
|
|||
|---|---|---|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 2.08 mg/mL (3.58 mM) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), suspension solution; with sonication.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (3.58 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (3.58 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: 40 mg/mL (68.90 mM) in 50% PEG300 50% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication (<60°C). Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.7226 mL | 8.6128 mL | 17.2256 mL | |
| 5 mM | 0.3445 mL | 1.7226 mL | 3.4451 mL | |
| 10 mM | 0.1723 mL | 0.8613 mL | 1.7226 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT01272167 | Completed | Behavioral: Long-term grapefruit juice consumption |
Post-menopausal Status | University Hospital, Clermont-Ferrand | March 2010 | Not Applicable |
| NCT01423019 | Completed | Dietary Supplement: Advantra Z + Naringin + Hesperiden |
Weight Loss | Integrative Health Technologies, Inc. | October 2011 | Not Applicable |
| NCT03582553 | Completed Has Results | Dietary Supplement: Naringenin Other: Placebo |
Safety Issues Pharmacokinetics |
Pennington Biomedical Research Center | May 25, 2018 | Early Phase 1 |
| NCT03928249 | Completed | Dietary Supplement: Eriocitrin | Pre Diabetes | São Paulo State University | December 1, 2019 | Not Applicable |
|
|
|
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
